Short sellers have been quietly reloading into M even as the stock put on its best monthly performance in months — creating a notable tension heading into this week's Q1 earnings release.
The short interest story is the standout this week. Bearish positioning has climbed sharply, rising 8% in a single week and nearly 19% over the past month to reach 12.3% of the free float — up from roughly 10.3% in early May. That's a meaningful acceleration: shorts added the bulk of their new positions in a concentrated burst after May 26, when shares short jumped from around 30.7 million to over 33 million in just a few days. The ORTEX short score of 55.8, while moderately elevated, has eased slightly from a recent peak of 58.4 on May 27, suggesting the rebuild may be levelling off. Borrow costs tell a contrasting story — at 0.48%, they remain near a one-year low, down 7% on the week. Availability is extremely loose at 789%, meaning there are roughly eight shares available to borrow for every one already short. Bears face no squeeze pressure whatsoever in the lending market; the borrow pool is wide open for new entrants.
Options positioning has tilted modestly more constructive over the past two weeks. The put/call ratio has drifted below its 20-day average, currently at 0.90 against a mean near 0.97 — about 1.4 standard deviations below average. That reads as relative call-side activity increasing into earnings. Given the PCR range of 0.73 to 1.62 over the past year, today's reading is far from extreme, but the direction of travel is mildly bullish relative to recent norms.
The Street has been cool on M for several months. The consensus is a uniform Hold, with ten analysts rated there and no Outperforms. JP Morgan trimmed its target to $21 and Citigroup cut to $18, both in March, keeping neutral ratings. Telsey Advisory Group has anchored at Market Perform since then. The lone bull in the room is Jefferies with a Buy and a $27 target, while UBS maintains a Sell with a $9 target. The mean price target is $19.60 — roughly 10% below the current price of $21.67 — indicating the average analyst view is that the stock has already overshot fair value after its 10% one-month rally. The valuation reads modestly: P/E near 10x, EV/EBITDA at 5.6x, and price-to-book at 1.15x. None of those multiples are stretched for retail, but the bear case — margin compression from tariff headwinds, a 1.7% net sales decline, and EBITDA margins projected to fall from 6.3% to around 5% — gives the Street good reason to stay cautious.
The institutional picture is stable. BlackRock holds 10.7%, Dimensional 6.2%, and a cluster of quant-oriented managers including Arrowstreet and AQR have been building positions. The most recent insider activity, from early April, was a round of award grants followed immediately by open-market sales — the largest from an executive vice president who sold nearly $900,000 worth at $17.92. That was routine post-vesting activity, not a directional signal. The net 90-day insider position is marginally positive in share terms but immaterial. Among the closest US peers, KSS is the most correlated and had a standout week, up 19% — a significant divergence from M's flat week. DDS gained a more modest 2.8%.
The earnings history is thin on reaction data, but one prior event — a May 15 print — saw the stock gain 1.1% on the day and 12.8% over the following five sessions. Today, June 3, the Q1 announcement appears to have already landed. With shorts rebuilt to a one-month high, analysts broadly sceptical, and options leaning slightly call-side, the question now shifts to whether the company's Reimagined store format and ancillary revenue streams — credit card revenues up 17%, media network up 12.5% — can offset the headline margin pressure the bears have been pricing in.
See the live data behind this article on ORTEX.
Open M on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
